Embecta Corp. (NASDAQ:EMBC) Q4 2024 Earnings Conference Call November 26, 2024 8:00 AM ET Company Participants Pravesh Khandelwal - VP of IR Dev Kurdikar - President and CEO Jake Elguicze - CFO Conference Call Participants Marie Thibault - BTIG Operator Good day, and welcome to the Embecta Fourth Quarter of Fiscal Year 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Mr. Pravesh K ...

| --- | --- | |------------------------------|-------| | | | | | | | | | | Earnings Conference Call | | | | | | Fiscal Q4 and Full Year 2024 | | | | | | November 26, 2024 | | Forward-Looking Statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations reg ...

On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.The company reported quarterly sales of $286.1 million, up 1.5% year over year, beating the consensus of $277 million.“We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics…Additionally, the recent launch of our small-pack GLP-1 needle ...

Exhibit 99.1 Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs PARSIPPANY, N.J., November 26, 2024 (GLOBE NEWSWIRE) – Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. "We are ...

PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. "We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics. We continued to execute on our strategic priorities, and to date, our significant accomplishment ...

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the ...

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Thursday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the ...

Embecta Corp. (EMBC) recently announced the receipt of 510(k) clearance from the FDA for its proprietary disposable patch pump for insulin delivery. This development marks a critical step forward in diabetes care, particularly for individuals with Type 2 diabetes (T2D). With a focus on addressing the specific needs of T2D patients, this system represents a notable advancement in insulin delivery technology. The clearance of this insulin delivery system is expected to significantly enhance Embecta's market p ...

While 9 out of 10 people with diabetes are living with T2D, many of the automated insulin delivery solutions currently on the market were designed for people living with T1D. 300-unit insulin reservoir is more suitable for people with T2D who are interested in moving from multiple daily injections (MDI) to pump therapy, based on an average daily dose of 95.9 units of insulin.1 PARSIPPANY, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a ...

财务业绩 - 公司收入在三个月和九个月期间均有所下降，分别下降4.8%和0.2%[119][120] - 毛利润在三个月期间略有增加0.3%，但在九个月期间下降1.2%[117][118] - 营业收入在三个月期间增加9.0%，但在九个月期间下降28.2%[117][118] - 净利润在三个月期间下降3.3%，在九个月期间下降1.1%[117][118] - 美国市场收入在三个月和九个月期间分别下降6.7%和2.2%[121] - 国际市场收入在三个月期间下降2.5%，但在九个月期间增长2.0%[121] 成本和费用 - 成本产品销售下降14.7%至82.4百万美元，占收入比例下降至30.2%[122] - 成本产品销售增加1.8%至275.6百万美元，占收入比例上升至32.9%[123] - 销售及管理费用下降2.2%至85.7百万美元[124] - 销售及管理费用增加9.2%至268.3百万美元[126] - 研发费用下降9.7%至20.4百万美元[127] - 其他营业费用增加233.9%至93.5百万美元[128] - 利息费用净额增加2.9%至83.3百万美元[129] - 有效税率从24.4%上升至45.6%[132] 财务状况 - 总债务为16.00亿美元，加权平均债务成本为7.2%[136][137] - 经营活动产生的现金流入为9.1百万美元[145] - 应收账款增加是由于Embecta与BD之间的保理协议到期和终止,Embecta现负责收集各个地区的未收回应收账款[146] - 存货变动是由于为应对2024财年ERP系统和其他业务连续性流程上线而增加原材料采购和成品[146] - 应付账款和应计费用的变动主要是由于在截至2024年6月30日的9个月期间向供应商付款的时间性影响[146] - 与Becton, Dickinson and Company的应收/应付款变动主要是由于Embecta与BD之间的保理协议到期和终止[146] - 预付费用和其他变动主要是由于实施ERP系统等业务连续性流程,不再需要向BD支付代表第三方的未来付款[146] - 资本支出1,580万美元用于支持业务和运营的进一步扩张[146] - 支付股票激励相关税收导致现金流出280万美元[147] - 支付长期债务720万美元,支付融资租赁100万美元[147] - 支付股息2,580万美元[147] 业务发展 - 公司面临原材料成本上升、供应链中断等挑战，但目前已采取措施应对[113] - 公司计划在2023年12月向FDA提交首个自主研发的可穿戴胰岛素输送系统的510(k)申请[113]